atrial fibrillation
Conditions
Interventions
Apixaban_radiofrequency ablation
Apixaban_cryoablation
Sponsors
Tokyo Medical and Dental University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Patients who are indicated for catheter ablation for drug-resistant non-valvular paroxysmal AF in the Japanese Heart Rhythm Society Guidelines 2)Patients who undergo the first catheter ablation while taking apixaban 3)Patients of age between 20 and 85 years 4)Patients for whom consent for participation in this study have been obtained in writing
Exclusion criteria
Exclusion criteria: Patients with a history of hypersensitivity to the components of apixaban. Patients with clinically significant bleeding symptoms. Patients with blood clotting defect and liver disease at clinically significant bleeding risk.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite of major bleedings and thromboembolism during perioperative period and within 4 weeks after the surgery. | — |
Secondary
| Measure | Time frame |
|---|---|
| Recurrence of AF during the follow-up period (because the presence or absence of recurrence may be associated with the development of embolic events), non-major bleeding, pericardial effusions not requiring drainage. | — |
Countries
Japan
Contacts
Public ContactAtsuhiko Yagishita
Tokyo Medical and Dental University Department of Advanced technology in medicine
Outcome results
None listed